Coreline Soft Expands AI Lung Screening Technology into Vietnam’s Smart Hospital Ecosystem

Leveraging Korea’s national screening expertise, the company supplies comprehensive AI chest diagnostics to Hanoi’s GC & Phenikaa Healthcare Center, establishing a strategic bridgehead into Asia’s premium screening market.

On December 23, Coreline Soft announced the deployment of its AI chest diagnosis platform, AVIEW LCS Plus, at GC & Phenikaa Healthcare Center, a facility established through a joint venture between GC Group and Phenikaa Group.

The GC & Phenikaa Healthcare Center, created through a joint venture between GC Group and Vietnam’s Phenikaa Group, is drawing attention as a model aligned with the Vietnamese government’s smart hospital and digital healthcare transformation policies. The center held its opening ceremony on the 5th.

The agreement marks GC Green Cross’s expansion into Vietnam’s premium screening market, following its operations at the Gangnam and Gangbuk Centers in Korea. It also signals an acceleration of the two companies’ shared global healthcare strategy.

Vietnam is experiencing rapid growth in demand for preventive care and early screening, supported by policies that encourage imports of medical equipment. Premium examination centers concentrated in Hanoi and Ho Chi Minh City cater to high-income and middle-class patients, as well as expatriates, and have been proactive in adopting advanced imaging and diagnostic technologies. Recognizing Vietnam’s open medical environment as a new growth engine, GC Green Cross iMed made a strategic decision to enter the local market. Through collaboration with GC & Phenikaa Healthcare Center—one of Hanoi’s leading premium medical institutions—the partners aim to introduce a new paradigm for AI-based screening in Vietnam.

The newly deployed AVIEW LCS Plus is an integrated solution that enables comprehensive analysis of pulmonary nodules, emphysema, and coronary artery calcification using a single low-dose chest CT scan. Core capabilities—including automated lesion detection and quantification, 3D stereoscopic visualization reports, and a user-friendly interface—enhance diagnostic accuracy and clinical efficiency. The platform also improves communication by helping examinees intuitively understand complex medical information and actively engage in their own health management.

By adopting AVIEW LCS Plus, GC & Phenikaa Healthcare Center has established a next-generation screening environment that delivers precise diagnosis of major thoracic diseases while minimizing radiation exposure. Yang Song-hyeon, CEO of GC & Phenikaa Healthcare Center, said, “With the opening of GC & Phenikaa Healthcare Center in Vietnam, we can deliver AI-powered precision screening services at a level comparable to Korea. Building on our successful first step in Asia, we aim to set a new global standard for premium health screening.”

Kim Jin-guk, CEO of Coreline Soft, added, “GC & Phenikaa Healthcare Center is a leading premium facility in Hanoi, operating smart examination systems such as HIS, LIS, PACS, and RFID. It is an ideal partner for realizing the clinical value of AVIEW LCS Plus. Together with global partners, we will continue to expand the culture of AI-enabled early screening, contributing to improved access to care and higher quality healthcare worldwide.”

According to Grand View Research, the global AI healthcare market is projected to grow from USD 22.45 billion in 2023 to USD 208.23 billion by 2030, representing a compound annual growth rate (CAGR) of 37.5% between 2024 and 2030. In thoracic disease areas—including lung cancer—diagnostic demand is rising rapidly, driven by population aging, smoking prevalence, and environmental factors.

link